©DANIEL ROUSSELOT/Sanofi

Setting the Stage for Sanofi’s 2021 Biopharma Vision at the J.P. Morgan Healthcare Conference

Originally published on LinkedIn by Dietmar Berger, Global Head of Development & CMO and Frank Nestle, Global Head of Research and Chief Scientific Officer at Sanofi

The start of a new year is always a special time for the biopharmaceutical industry. With the J.P. Morgan (JPM) Healthcare Conference starting today, biopharma companies like Sanofi will share important pipeline updates and forecasts for the year ahead.

Before we look ahead to 2021, we want to reflect on the unprecedented year we just left behind. Of course, Sanofi spent much of 2020 rising to the challenge of the COVID-19 pandemic, working diligently and with speed to develop multiple vaccine candidates, while also progressing our research and development programs. In the midst of the pandemic, 2020 was a year of increasing focus as Sanofi executed against our new research and development strategy to make an impact in diseases with high unmet needs in immunology and inflammation, oncology, neuroscience, rare disease and vaccines. Both by necessity and design, we reinvented how we work, prioritizing faster and more rigorous decision-making and urgency of execution in the pursuit of medical breakthrough therapies.

For Sanofi, 2021 has the potential to be transformative. During this year’s virtual JPM conference, we’re excited to share how we have continued to expand the druggable universe by further building out our technology platforms and diverse modalities that allow us to address a range of disease challenges with a set of novel tools. Through the application of cutting-edge science, we are creating new synthetic biology solutions for the drugs of the future and using cell and gene therapy for tackling both common and rare diseases. We are also leveraging our long heritage in antibodies and oncology to fuel breakthrough work in antibody-drug conjugates (ADCs), pursuing with determination a development path in solid tumors.  We are expanding our knowledge of fundamental disease biology in areas such as cancer and type 2 inflammation, with the goal of innovating more effectively or studying mechanisms of resistance to understand inadequate treatment response and new ways to help more patients.

Sanofi has also continued to advance innovation thanks to our business development and partnership strategy. After acquiring Synthorx, its synthetic biology platform and its non-alpha IL-2 molecule and partnering with Revolution Medicines on the development of cancer drugs against SHP2, we advanced our research in cancer toward a potential best-in-class portfolio. We’re continuing to expand our state-of-the-art technologies in selected therapeutic areas through our recent partnerships and acquisitions, including Kiadis’ K-NK cell “off the shelf” cell therapy platform for cancer, Principia’s BTK inhibitors for a range of inflammatory diseases including multiple sclerosis and pemphigus vulgaris, Kymera Therapeutics’ IRAK4 protein degrader approach for immuno-inflammatory diseases, and Translate Bio’s mRNA vaccine platform.

These investments in science drive our pipeline and help us make significant progress in our efforts to deliver the next generation of life changing medicines. In 2021, we’ll continue to pursue important advancements in our robust pipeline, including key milestones for our priority assets and beyond. We also hope to receive a number of key regulatory approvals this year as we work to bring our medicines to new and expanded patient populations.

At our JPM presentation, Sanofi will highlight in more detail our progress in the past year as well as the outlook for our pipeline. We look forward not only to sharing our updates, but also to learning of the advancements made by our industry colleagues across biopharma as we all set our sights for continued innovation in 2021. Indeed, taking into account recent progress on COVID-19 vaccines and the united efforts of the biopharma and scientific community, there’s no better year to celebrate the significant impact that science can have on society and look ahead with optimism to a bright future.

 

Latest News

President Joe Biden signs his first executive orders in the Oval Office

Biden Administration Already Hard at Work Enacting Numerous Beneficial Policies; Amanda Gorman is America’s New Superstar Poet; and More

President Joe Biden sworn in and new administration already hard at work. Just hours after his emotional, star-studded and highly protected inauguration took place on Jan. 20, President Joe Biden is already working on fulfilling campaign promises and undoing some of the most egregious acts carried out by his predecessor….

Trump commission attempts racist whitewashing of history

Trump Commission Attempts Racist Whitewashing of History; Colorado Rep. Lauren Boebert Probed for Potential Role in Capitol Insurrection; and More

Trump commission’s “1776 Report” attempts racist whitewashing of history In the highly controversial “1776 Report” released by the Trump administration yesterday, the outgoing GOP party doesn’t just try to present a nonpartisan, “patriotic” look at the nation’s history (as the President had promised the report would do) it fully rewrites…

Boeing Elects Lynne Doughtie to Board of Directors, Following Resignation of Director Caroline Kennedy

Originally published on boeing.mediaroom.com. The Boeing Company (No. 27 on The 2020 DiversityInc Top 50 Companies for Diversity list) board of directors today announced that Lynne Doughtie has been elected to the board, replacing Caroline Kennedy who has resigned following three years of dedicated service. Doughtie, 58, retired from KPMG in 2020, after serving as U.S. Chairman and…

Flint, Michigan water plant

Ex-Michigan Governor Charged for Racist Lead Poisoning of Flint Water Supply; COVID-19 Vaccines Not Increasing in Availability; Democrats Plan to Repeal Trump Rules; and More

Former Michigan Governor formally charged for poisoning thousands of predominantly Black Flint citizens with water containing lead. In 2014, when the city of Flint was forced by the state to begin taking its water supply from the Flint river rather than using water from nearby Detroit as it had for…